Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP1 inhibits enzalutamide. 2 / 2

| 2

➶

reach

"Furthermore, we found that USP1 knockdown reduced tumorigenesis and promoted PC cell response to therapeutic agent enzalutamide in a KDM4A dependent manner."

32133742

➶

reach

"The supportive evidence is as follows : (i) USP1 knockdown decreased PC cell proliferation in vitro and tumorigenesis in vivo, and promoted the response to therapeutic agent enzalutamide; and (ii) inhibition of USP1 sensitized cancer cells to therapeutic agent enzalutamide, whereas this effect was blunted by overexpression of KDM4A."

32133742

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...